Título :	Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism: a Latin American perspective
Tipo de documento :	documento electrónico
Autores :	Kenny Mauricio Gálvez Cárdenas,
Fecha de publicación :	2022
Títulos uniformes :	Clinical and Applied Thrombosis/Hemostasis
Idioma :	Inglés (eng)
Palabras clave :	anticoagulation  cancer  venous thromboembolism
Resumen :	Venous thromboembolism (VTE) is a leading cause of morbidity and mortality in patients with cancer. On the basis of results from randomized controlled trials, direct oral anticoagulants (DOACs) are now recommended for the treatment of cancer-associated VTE. The decision to use a DOAC requires consideration of bleeding risk, particularly in patients with gastrointestinal (GI) malignancies, the cost-benefit and convenience of oral therapy, and patient preference. While efficacy with apixaban, edoxaban, and rivaroxaban versus dalteparin has been consistent in the treatment of cancer-associated VTE, heterogeneity is evident with respect to major GI bleeding, with an increased risk with edoxaban and rivaroxaban but not apixaban. Although cost and accessibility vary in different countries of Latin America, DOACs should be considered for the long-term treatment of cancer-associated VTE in all patients who are likely to benefit. Apixaban may be the preferred DOAC in patients with GI malignancies and LMWH may be preferred for patients with upper or unresected lower GI tumors. Vitamin K antagonists should only be used for anticoagulation when DOACs and low molecular weight heparin are inaccessible or unsuitable.
Mención de responsabilidad :	Rodrigo Abensur Athanazio, José Manuel Ceresetto, Luis Javier Marfil Rivera, Gabriela Cesarman-Maus, Kenny Galvez, Marcos Arêas Marques, Aldo Hugo Tabares, Carlos Alberto Ortiz Santacruz, Fernando Costa Santini, Luis Corrales, Alexander T Cohen
Referencia :	Clin Appl Thromb Hemost. Jan-Dec 2022;28:10760296221082988.
DOI (Digital Object Identifier) :	10.1177/10760296221082988
PMID :	35261295
Derechos de uso :	CC BY-NC
En línea :	https://journals.sagepub.com/doi/10.1177/10760296221082988
Enlace permanente :	https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis

Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism: a Latin American perspective [documento electrónico] / Kenny Mauricio Gálvez Cárdenas,  . - 2022.
Obra : Clinical and Applied Thrombosis/Hemostasis

Idioma : Inglés (eng)

Palabras clave :	anticoagulation  cancer  venous thromboembolism
Resumen :	Venous thromboembolism (VTE) is a leading cause of morbidity and mortality in patients with cancer. On the basis of results from randomized controlled trials, direct oral anticoagulants (DOACs) are now recommended for the treatment of cancer-associated VTE. The decision to use a DOAC requires consideration of bleeding risk, particularly in patients with gastrointestinal (GI) malignancies, the cost-benefit and convenience of oral therapy, and patient preference. While efficacy with apixaban, edoxaban, and rivaroxaban versus dalteparin has been consistent in the treatment of cancer-associated VTE, heterogeneity is evident with respect to major GI bleeding, with an increased risk with edoxaban and rivaroxaban but not apixaban. Although cost and accessibility vary in different countries of Latin America, DOACs should be considered for the long-term treatment of cancer-associated VTE in all patients who are likely to benefit. Apixaban may be the preferred DOAC in patients with GI malignancies and LMWH may be preferred for patients with upper or unresected lower GI tumors. Vitamin K antagonists should only be used for anticoagulation when DOACs and low molecular weight heparin are inaccessible or unsuitable.
Mención de responsabilidad :	Rodrigo Abensur Athanazio, José Manuel Ceresetto, Luis Javier Marfil Rivera, Gabriela Cesarman-Maus, Kenny Galvez, Marcos Arêas Marques, Aldo Hugo Tabares, Carlos Alberto Ortiz Santacruz, Fernando Costa Santini, Luis Corrales, Alexander T Cohen
Referencia :	Clin Appl Thromb Hemost. Jan-Dec 2022;28:10760296221082988.
DOI (Digital Object Identifier) :	10.1177/10760296221082988
PMID :	35261295
Derechos de uso :	CC BY-NC
En línea :	https://journals.sagepub.com/doi/10.1177/10760296221082988
Enlace permanente :	https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis